Welcome to our dedicated page for NOVO NORDISK A S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novo Nordisk A/S filings document the Danish healthcare company's financial reporting, product portfolio, pipeline progress and capital structure as a foreign private issuer. Form 6-K reports include operating and financial results, commercial updates for diabetes and obesity medicines, regulatory and clinical disclosures for products such as Wegovy, and development updates in areas including sickle cell disease.
The filing record also covers B-share repurchase programs, treasury-share ownership, share-capital information, governance matters and risk-related disclosures. These reports connect Novo Nordisk's chronic-disease business, GLP-1 franchise, biopharmaceutical research and shareholder-capital actions to formal regulatory disclosure.
Novo Nordisk A/S (NVO) reports progress on its ongoing share repurchase programme conducted under EU Safe Harbour Rules. The company plans to repurchase B shares for up to DKK 15 billion during a 12‑month period beginning 4 February 2026, as part of its capital allocation strategy.
Under the sub-programme initiated on 6 May 2026, Novo Nordisk may buy back B shares for up to DKK 11,200,000,010.45 through 1 February 2027. As of 28 August 2026, it has repurchased 30,979,179 B shares at an average price of DKK 281.08, for a total of DKK 8,707,673,805. Novo Nordisk now holds 45,019,876 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S (NVO) reports progress on its ongoing B share repurchase programme conducted under EU Safe Harbour Rules. The current sub-programme, running from 6 May 2026 to 1 February 2027, authorises repurchases of B shares for up to DKK 11,200,000,010.45, as part of an overall 12‑month share repurchase programme of up to DKK 15 billion beginning 4 February 2026.
Between 17 and 21 August 2026, the company repurchased 1,045,000 B shares, bringing the accumulated amount under the 6 May programme to 15,170,000 B shares with a transaction value of DKK 4,590,476,842. Novo Nordisk now holds 43,969,876 B shares as treasury shares, equal to 1.0% of the total share capital of 4,465,000,000 A and B shares. Since 4 February 2026, it has repurchased 29,929,179 B shares at an average price of DKK 280.34, for a total of DKK 8,390,476,831.
Novo Nordisk A/S reports ongoing activity under its B share repurchase programme conducted under EU Market Abuse Regulation Safe Harbour rules. This programme is part of an overall plan to repurchase up to DKK 15 billion of B shares during the 12-month period beginning 4 February 2026. A specific sub-programme initiated on 6 May 2026 allows repurchases of B shares for up to DKK 11,200,000,010.45 through 1 February 2027.
Following transactions from 10–14 August 2026, accumulated repurchases under the sub-programme total 14,125,000 B shares with a value of DKK 4,281,660,830. As of 14 August 2026, since 4 February 2026 Novo Nordisk has repurchased 28,884,179 B shares at an average price of DKK 279.80 per share, for a total of DKK 8,081,660,819. The company now holds 42,924,876 B shares as treasury shares, corresponding to 1.0% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S provides an update on its ongoing B-share repurchase activity. As part of an overall programme of up to DKK 15 billion over 12 months beginning 4 February 2026, the company is executing a sub-programme, initiated 6 May 2026, to repurchase B shares for up to DKK 11,200,000,010.45 through 1 February 2027.
Between 4 and 7 August 2026, Novo Nordisk repurchased a total of 820,000 B shares, bringing the accumulated amount under this sub-programme to 13,125,000 B shares for DKK 3,980,067,920. Separate incentive-related transactions led to a net transfer of 3,144,604 shares from Novo Nordisk during the same period, outside the Safe Harbour programme. After these transactions, Novo Nordisk holds 41,924,876 B shares as treasury shares, equal to 0.9% of its total share capital of 4,465,000,000 A and B shares. Since 4 February 2026, the company has repurchased 27,884,179 B shares at an average price of DKK 279.01, for a total of DKK 7,780,067,909.
Novo Nordisk A/S reports transactions in its B shares by members of the board of directors, executives and their associated persons, as required under Article 19 of the EU market abuse regulation. The reported transactions all relate to the vesting of shares under the Restricted Shares programme "Novo Nordisk 100th Anniversary Shares".
For each named board member and executive, including the President and CEO and several Executive Vice Presidents, 74 B shares (ISIN DK0062498333) vested at a reference price of DKK 294.30 per share, corresponding to an aggregated value of DKK 21,778.20 per individual transaction. All vestings occurred on 5 August 2026 outside a trading venue. Novo Nordisk notes its global healthcare focus on serious chronic diseases, with about 66,700 employees in 80 countries and products marketed in around 170 countries.
Novo Nordisk reported Q2 2026 adjusted sales of DKK 78,488 million, up 7% at constant exchange rates (CER), and adjusted operating profit of DKK 33,389 million, up 11% at CER. The adjusted figures exclude non-recurring provision reversals related to the US 340B Drug Pricing Program and exclude DKK 6.3 billion of non-recurring, non-cash impairment charges on intangible pipeline assets, including monlunabant.
For 2026, the company raised its full-year outlook at CER, now guiding adjusted sales growth of 0% to -6% and adjusted operating profit growth of 0% to -6%, an improvement from prior guidance of -4% to -12%. The higher guidance is driven by increased expectations for GLP-1 product sales.
Novo Nordisk A/S is continuing its B-share buybacks under a programme initiated 6 May 2026 within EU Safe Harbour Rules, as part of an overall share repurchase programme of up to DKK 15 billion during a 12-month period beginning 4 February 2026. Under the 6 May 2026 programme, the company may repurchase B shares for up to DKK 11,200,000,010.45 between 6 May 2026 and 1 February 2027.
Between 27 July and 3 August 2026, Novo Nordisk executed multiple daily B-share purchases, bringing total repurchases under the 6 May 2026 programme to 12,305,000 B shares for DKK 3,733,256,468. After these transactions, it holds 44,249,480 B shares of DKK 0.10 as treasury shares, equal to 1.0% of its 4,465,000,000 A and B shares. Since 4 February 2026, the company has repurchased 27,064,179 B shares at an average price of DKK 278.35 per share, for a total of DKK 7,533,256,457.
Novo Nordisk A/S reported headline results from the ZEUS phase 3 cardiovascular outcomes trial of ziltivekimab in more than 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. Ziltivekimab reduced free IL‑6 and hsCRP as expected, but did not lower major adverse cardiovascular events versus placebo (hazard ratio 0.99; 95% confidence interval 0.88 to 1.11).
Overall adverse-event rates were similar between groups, although serious infections were more frequent with ziltivekimab; no difference in all-cause mortality was seen. Novo Nordisk plans to continue the HERMES and ARTEMIS cardiovascular trials, with results anticipated in the first half of 2027. The ZEUS outcome will not change the company’s adjusted operating profit outlook for 2026 but will trigger a non-cash impairment charge in Q3 2026.
Novo Nordisk A/S reports progress on its B share repurchase programme. Under a sub-programme started 6 May 2026 and running to 1 February 2027, the company may buy back B shares for up to DKK 11,200,000,010.45 as part of a broader DKK 15 billion 12‑month programme beginning 4 February 2026.
As of 24 July 2026, it has repurchased 25,919,179 B shares at an average price of DKK 276.33 per share, for a total of DKK 7,162,368,893. Following recent purchases, Novo Nordisk holds 43,104,480 B shares of DKK 0.10 as treasury shares, equal to 1.0% of the company’s 4,465,000,000 A and B shares including treasury shares.